Exact sciences

Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS® 2022

Retrieved on: 
Tuesday, December 6, 2022
Recurrence, Poster, MDM, Breast cancer, ESR1, National Cancer Institute, Research, Cancer, Woman, Guideline, Database, Gene, Risk, Precision, Physician, Prognosis, Trial, Ageing, Stemmer, Treatment, Lymph, BRCA2, Genomic Health, White, NCI, Oncotype (Denmark), Security (finance), Exact Sciences (company), RT-PCR, MD, Diagnosis, DNA, The New England Journal of Medicine, Exact sciences, Radiation, MRD, RNA, Mutation, Breast, Electric Bond and Share Company v. Securities and Exchange Commission, CT, Patient, Annual report, ER, News, Intron, Health, Mount Sinai Health System, Birth control, Pharmaceutical industry, Medical imaging, Vaccine, Silviculture, Wood drying

"The breadth of evidence presented at SABCS 2022 showcases Exact Sciences' growing Precision Oncology portfolio and commitment to personalizing cancer care and potentially enabling better outcomes at every step," said Rick Baehner, M.D., chief medical officer of Precision Oncology.

Key Points: 
  • "The breadth of evidence presented at SABCS 2022 showcases Exact Sciences' growing Precision Oncology portfolio and commitment to personalizing cancer care and potentially enabling better outcomes at every step," said Rick Baehner, M.D., chief medical officer of Precision Oncology.
  • In breast cancer, the Oncotype DX Breast Recurrence Scoretest is the only test shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.
  • The Oncotype DX test is recognized as a standard of care and is included in all major breast cancer treatment guidelines.
  • For more information, please visit the company's website at exactsciences.com, follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

American Cancer Society Adds Four New Members to Its Board of Directors

Retrieved on: 
Monday, December 5, 2022
Singular, CGMA, Cancer, Health equity, Pellene, Foundation Medicine, Qurate Retail Group, The Home Depot, LLP, American Cancer Society Cancer Action Network, Physician, CIO, Chairperson, American Cancer Society, Health, Growth, Trupanion, Jewish Leadership Council, Woman, MD, Trustee, Gap Inc., Personalized medicine, SMFR, Roche, News, ACS, PricewaterhouseCoopers, Bryant University, Information technology, MBA, Exact sciences, Acquisition, PETS, Duke University, Thomas Jefferson University, Section 32, Doctor of Philosophy, CPA, Research, Committee on Finance, Volunteering, Insurance, GE Healthcare, HSM, Holding company, Management, Pharmaceutical industry

ATLANTA, Dec. 5, 2022 /PRNewswire/ -- The American Cancer Society (ACS) has named four new members to its board of directors, with all terms beginning on January 1, 2023.

Key Points: 
  • ATLANTA, Dec. 5, 2022 /PRNewswire/ -- The American Cancer Society (ACS) has named four new members to its board of directors, with all terms beginning onJanuary 1, 2023.
  • The ACS Board of Directors consists of 22 members, which includes five officers and 17 directors.
  • He has served on the American Cancer Society of Puerto Rico Board of Directors since 1990 including serving as president of the board.
  • "We are grateful to the outgoing American Cancer Society board members for their dedication and commitment to improving the lives of people with cancer and their families," said Michael Marquardt, 2022 Board Chair.

MDxHealth Provides Business Update

Retrieved on: 
Tuesday, November 29, 2022
Urology, Palmetto, NCCN, Patient, Growth, Methylation, Diagnosis, Communication, TA, LCD, Increa Park, Biomarker, Oncotype (Denmark), Prostate, Physician, Social media, American Urological Association, Medicare, Prognosis, Cancer, Risk, Prostate cancer, Exact sciences, GPS, Acquisition, Medical device, Medical imaging, Select

The Select mdx TA has already been submitted and we are engaged in an interactive review process with MolDX.

Key Points: 
  • The Select mdx TA has already been submitted and we are engaged in an interactive review process with MolDX.
  • In August 2022, mdxhealth announced that it acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences, further solidifying the Companys leadership in the precision diagnostics urology market.
  • Michael K. McGarrity, CEO of mdxhealth, commented: Securing Medicare reimbursement for new molecular diagnostic technologies is now a more rigorous and iterative process under the new Foundational LCD program.
  • Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer.

Global Epigenetics Market Analysis & Forecasts Report, 2016-2021, 2021-2026F, 2031F Featuring Major Players - Illumina, Thermo Fisher Scientific, Merck Millipore, Abcam, & Active Motif - ResearchAndMarkets.com

Retrieved on: 
Monday, November 28, 2022
Biotechnology, Genetics, Health, EFTA, Growth, European Commission–AstraZeneca COVID-19 vaccine dispute, Diagnosis, CDC, Union, Prevalence, Korea Disease Control and Prevention Agency, European Free Trade Association, Joint Research Centre, Gene, Acceleration, DNA, LHSC, VUS, Children's Hospital at London Health Sciences Centre, Genomics, European Commission, London Health Sciences Centre, Cancer, Genetic testing, Exact sciences, DNA methylation, Acquisition, Renewable energy, Vaccine, Pharmaceutical industry, EU

The growing prevalence of cancer and other diseases is significantly driving the growth of the epigenetics market.

Key Points: 
  • The growing prevalence of cancer and other diseases is significantly driving the growth of the epigenetics market.
  • The regions covered in the epigenetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The key players in the epigenetics sector are focusing on developing various technologically advanced products and services to strengthen their position in the market.
  • The countries covered in the epigenetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

Europe Biopsy Devices Market Analysis Report 2022: Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 28, 2022
Health, Oncology, COVID-19, Incidence, Genomics, Biopsy, Diagnosis, Infection, Economy of the European Union, Cell, Bio-Rad Laboratories, Hospital, Roche Diagnostics, Ultrasound-guided hip joint injection, MI, Patient, Thermo Fisher Scientific, Becton, Cancer, Quest Diagnostics, Prostate, MRI, Lung cancer, Becton, Dickinson and Company headquarters, Imaging, Surgeon, Radiology, Research, Prostate cancer, Exact sciences, Insight, Association for Molecular Pathology v. Myriad Genetics, Inc., Cardiology, Liquid biopsy, Breast cancer, Investment, CT, Qiagen, Medical imaging, Pharmaceutical industry, Coronavirus, Growth

The "Europe Biopsy Devices Market, Size, Forecast 2022-2027, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Biopsy Devices Market, Size, Forecast 2022-2027, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Biopsy guiding systems, needle-based biopsy guns, biopsy needles, and biopsy forceps are the most often used biopsy instruments.
  • Increased investments in R&D activities are driving the Europe Biopsy Devices Market.
  • According to our analysis, the Europe Biopsy Devices Market was negatively impacted from the end of 2019 to the beginning of 2020.

New data reveal that 4 out of 5 breast cancer patients eligible for genomic testing are not told it is available to them

Retrieved on: 
Monday, November 21, 2022
Patient, Knowledge, Physician, Policy, Caregiver, Survivor, Myc, Medicine, International, Cancer, Precision medicine, Exact sciences, Hope, Breast cancer, Woman, CPE, Medical imaging, Dietary supplement, Pharmaceutical industry, Health insurance

Genomic testing allows eligible patients with early-stage breast cancer the opportunity to benefit from personalised or precision medicine.

Key Points: 
  • Genomic testing allows eligible patients with early-stage breast cancer the opportunity to benefit from personalised or precision medicine.
  • Therefore, it can spare many women with early-stage breast cancer from chemotherapy and the associated side effects.
  • Eighty-three percent (83%) of respondents were breast cancer patients, 50% of whom were eligible for genomic testing.
  • myC is a CPE initiative which aims to raise awareness of the benefits and values of genomic testing in cancer.

United States Liquid Biopsy Market Report 2022: Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 25, 2022
Biotechnology, Health, Oncology, COVID-19, Liquid biopsy, EVS, Genomics, Diagnosis, Laboratory, Blood, DNA, Hospital, Urine, Roche Diagnostics, Projection, Circulating tumor DNA, Patient, Liquid, Government, Association for Molecular Pathology v. Myriad Genetics, Inc., Thermo Fisher Scientific, Biomarker, Exosome, Organic acid, American Cancer Society, Lung cancer, Chinese, Colorectal cancer, Prognosis, Cancer, Neoplasm, Research, Prostate cancer, Exact sciences, MBS, Coronavirus, Extracellular vesicle, Breast cancer, Large-cell lung carcinoma, Woman, Infection, Qiagen, Person, Medical imaging, Glossary of biology, Growth

The "United States Liquid Biopsy Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Liquid Biopsy Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • However, the reduced sensitivity of some liquid biopsies may limit market growth in the United States throughout the foreseeable period.
  • The liquid biopsy market in the United States is split into four categories: lung cancer, breast cancer, colorectal cancer, and prostate cancer.
  • The liquid biopsy market in the United States is classified into three categories: kits and consumables, instruments, and services.

Silicon Catalyst Announces EXOKĒRYX as the Newest Portfolio Company Admitted to the Incubator

Retrieved on: 
Friday, November 18, 2022
Ecosystem, SAN, Cancer, Growth, Silicon, Mentorship, Biotechnology, GlobalFoundries, Intel, Marketing, Research, Multimedia, Exact sciences, Patient, Electronics, Liquid biopsy, Incubator, Exosome, Diagnosis, Disease, Biomarker, Medical imaging, SEMATECH

SAN DIEGO and SILICON VALLEY, Calif., Nov. 18, 2022 /PRNewswire/ -- Silicon Catalyst, the world's only incubator focused exclusively on accelerating semiconductor solutions, is pleased to announce that EXOKĒRYX has been accepted into the Silicon Catalyst Incubator program. With their admission into the Incubator, EXOKĒRYX will have direct access to the products and services of the Silicon Catalyst comprehensive ecosystem of In-Kind Partners and a wealth of industry expertise through the advisor and investor network.

Key Points: 
  • SAN DIEGO and SILICON VALLEY, Calif., Nov. 18, 2022 /PRNewswire/ -- Silicon Catalyst, the world's only incubator focused exclusively on accelerating semiconductor solutions, is pleased to announce that EXOKRYX has been accepted into the Silicon Catalyst Incubator program.
  • EXOKRYX joined Silicon Catalyst to take advantage of the extensive array of resources provided by the Silicon Catalyst ecosystem to assist with the development, commercialization, and market traction.
  • More than 700 startup companies worldwide have engaged with Silicon Catalyst and the company has admitted 88 exciting companies.
  • The Silicon Catalyst Angels was established in July 2019 as a separate organization to provide access to seed and Series A funding for Silicon Catalyst portfolio companies.

Kalorama Information: 20 Companies That Have Worked Out Molecular Diagnostic Deals Recently

Retrieved on: 
Thursday, November 17, 2022
Knowledge, Medicine, Bio-Rad Laboratories, Knowledge-centered support, Biotechnology, Partnership, Single-cell analysis, Software, Consortium, Roche, Genomics, AstraZeneca, LRRK2, NGS, IVD, Exact sciences, Patient, Parkinson's disease, Biosensor, Curiosity, SD, Brain, Architecture, Medical device, Medical imaging, Pharmaceutical industry, Antibiotics, Science, Ultima, Meridian, Pirch (company)

ARLINGTON, Va., Nov. 17, 2022 /PRNewswire-PRWeb/ -- According to Kalorama Information's The World Market for Molecular Diagnostics Tests, 11th Edition, the demand for molecular in vitro diagnostics (IVD) means that very often a single firm cannot go it alone and must find partners.

Key Points: 
  • The demand for molecular in vitro diagnostics (IVD) means that often a single firm cannot go it alone and must find partners.
  • Here are 10 key recent deals in the market.
  • Kalorama Information, part of Science and Medicine Group, is the leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, medical devices, and pharmaceuticals.
  • Science and Medicine Group supports companies seeking to commercialize the rapidly changing marketplace at the intersection of science, medicine, and technology.

Matt Franklin, MBA, appointed as Biofidelity Non-Executive Director

Retrieved on: 
Thursday, November 17, 2022
RESEARCH, Health, MBA, Physician, University, Master of Business Administration, PARK, Multimedia, Exact sciences, Patient, Noise, Business administration, Oncology, Foundation Medicine, Genomics, Management, Hospital, Northwestern University

CAMBRIDGE, England and RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2022 /PRNewswire/ -- Biofidelity, a revolutionary genomic technology company, has expanded its Board of Directors to include Matt Franklin, MBA, who will join as a Non-Executive Director effective immediately.

Key Points: 
  • CAMBRIDGE, England and RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2022 /PRNewswire/ -- Biofidelity, a revolutionary genomic technology company, has expanded its Board of Directors to include Matt Franklin, MBA, who will join as a Non-Executive Director effective immediately.
  • Matt brings extensive, relevant experience and a unique track record of driving revenue growth for genomics companies in both the specialty laboratory and distributed product manufacturing segments.
  • Regarding his appointment, Matt commented, "I am delighted to join Biofidelity at this very exciting time in the Company's journey.
  • Biofidelity is a revolutionary genomic technology company dedicated to removing the noise from genomic analysis to unleash its potential to transform human health.